Search results (7850)
« Back to PublicationsAppropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
A roadmap of priority evidence gaps for the co-implementation of malaria vaccines and perennial malaria chemoprevention
Grant J. et al, (2025), Malaria Journal, 24
Developing the next-generation of adenoviral vector vaccines.
Sampson AT. et al, (2025), Human vaccines & immunotherapeutics, 21
Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.
Kantor J. et al, (2025), Human vaccines & immunotherapeutics, 21
Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in European older adults: a multi-country analysis
Li X. et al, (2025), BMC Medicine, 23
Respiratory syncytial virus hospitalisation by chronological month of age and by birth month in infants
Guo L. et al, (2025), Nature Communications, 16
Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.
McDaniel JR. et al, (2025), The Journal of experimental medicine, 222
Tuberculosis in patients with systemic lupus erythematosus
Ongarj J. et al, (2025), Frontiers in Immunology, 16
Dosing interval is a major factor determining the quality of T cells induced by SARS-CoV-2 mRNA and adenoviral vector vaccines
Murray SM. et al, (2025), Science Immunology, 10
MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines
Amini A. et al, (2025), Science Immunology, 10
Diagnostic ultrasound to inform the surgical approach to cesarean delivery in patients at high risk for placenta accreta spectrum disorders
Aryananda RA. et al, (2025), American Journal of Obstetrics and Gynecology
Evaluation of 1<sup>st</sup> WHO anti-malaria reference reagent for competition ELISA harmonisation and development of ADAMSEL analytical platform.
Khatri B. et al, (2025), Biologicals : journal of the International Association of Biological Standardization
Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: Results from COV-BOOST trial.
Janani L. et al, (2025), The Journal of infection, 91
Human tonsil organoids reveal innate pathways modulating humoral and cellular responses to ChAdOx1.
Pudjohartono MF. et al, (2025), PLoS pathogens, 21
Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil
Costa Clemens SA. et al, (2025), Mayo Clinic Proceedings Innovations Quality and Outcomes, 9
The waning of maternal measles antibodies: A multi-country maternal-infant seroprevalence study
Tiley KS. et al, (2025), Journal of Infection, 91, 106531 - 106531
Comparative performance of the InBios SCoV-2 DetectTM IgG ELISA and the in-house KWTRP ELISA in detecting SARS-CoV-2 spike IgG antibodies in Kenyan populations
Kutima B. et al, (2025), Wellcome Open Research, 9, 349 - 349
Capsid Restructuring Activates Semi-Conservative dsRNA Transcription in Cystovirus ɸ6.
Ilca SL. et al, (2025), bioRxiv
Uncovering the genetic diversity of the malaria parasite antigen MSP2 across Sub-Saharan Africa
Zerebinski J. et al, (2025)
Salmonella Typhi gut invasion drives hypoxic immune subsets associated with disease outcomes
Bossel Ben-Moshe N. et al, (2025), Nature Communications, 16